Gabapentin (Epilepsy)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.34 [0.42, 4.34]0%5 studies9784not evaluable ROB-
Major congenital malformations1.48 [0.46, 4.79]0%5 studies9284serious ROB-
Congenital heart defects5.36 [0.58, 49.42]-1 study531not evaluable ROB-
Atrial septal defect--0 study-
Digestive system anomalies3.01 [0.15, 59.66]-1 study331not evaluable ROB-
Eye defects4.85 [0.09, 267.23]-1 study61not evaluable ROB-
Hypospadias1.62 [0.09, 29.34]-1 study631not evaluable ROB-
Limb defects4.23 [0.20, 89.96]-1 study231not evaluable ROB-
Minor congenital malformations5.91 [0.11, 330.07]-1 study51not evaluable ROB-
Neural Tube Defects7.05 [0.28, 176.78]-1 study131not evaluable ROB-
Oro-facial clefts7.05 [0.28, 176.78]-1 study131not evaluable ROB-

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)10.63 [0.54, 209.24]0%2 studies43not evaluable ROB-

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation--0 study-

Long term consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Behavioral disorders1.10 [0.38, 3.18]-1 study14not evaluable ROB-
Emotional disorders1.13 [0.39, 3.28]-1 study14not evaluable ROB-

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Intrauterine deaths (as a whole or unspecified)4.41 [0.49, 39.98]0%3 studies317not evaluable ROB-
Early intrauterine death (< 22 weeks)4.64 [0.23, 93.20]0%2 studies23not evaluable ROB-
Elective/induced termination of pregnancy2.33 [0.03, 182.92]-1 study2not evaluable ROB-
Therapeutic terminations of pregnancy2.33 [0.03, 182.92]-1 study2not evaluable ROB-
Late intrauterine deaths (> 22 weeks)47.00 [0.38, 5814.69]-1 study1not evaluable ROB-

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neuro-developmental disorders (as a whole)7.99 [0.44, 143.69]0%2 studies62not evaluable ROB-
ADHD (Attention deficit hyperactivity disorder): Risk0.87 [0.30, 2.52]-1 study14not evaluable ROB-
ASD (Autism spectrum disorder): Diagnosis17.00 [0.13, 2166.90]-1 study1not evaluable ROB-
ASD (Autism spectrum disorder): Risk17.00 [0.13, 2166.90]-1 study1not evaluable ROB-
Cognitive developmental disorders/delay (> 6 years old)1.33 [0.13, 13.89]-1 study414not evaluable ROB-
Language disorders/delay0.98 [0.10, 9.53]-1 study514not evaluable ROB-

Hide endpoints reported in only one study ...

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons